PMV Pharmaceuticals, a clinical-stage biotech company specializing in therapies targeting mutant p53 proteins, continues to advance its lead candidate rezatapopt through pivotal Phase 2 trials following FDA Fast Track designation. The company has incurred steep losses and negative operating cash flow as expected for its stage, underscored by increasing R&D expenses tied to clinical development efforts. PMV maintains a strong liquidity position with over $115 million in current assets and no revenues to date, aiming for NDA submission in early 2027 for platinum-resistant ovarian cancers harboring the TP53 Y220C mutation. Operational execution hinges on successful trial completion and securing additional financing given ongoing cash burn.